Previous close | 21.20 |
Open | 21.20 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 210.00 |
Expiry date | 2025-01-17 |
Day's range | 21.20 - 21.20 |
Contract range | N/A |
Volume | |
Open interest | 168 |
In the latest trading session, Novo Nordisk (NVO) closed at $126.16, marking a -1.93% move from the previous day.
A U.S. Senate committee said on Wednesday it had launched an investigation into the prices of Novo Nordisk's diabetes and weight loss drugs Ozempic and Wegovy in the United States. Senator Bernie Sanders, chair of the Senate Committee on Health, Education, Labor and Pensions, sent a letter to Novo's CEO seeking more information on U.S. prices for the two drugs, which are higher than the prices in other countries. The committee also asked Novo if it will substantially reduce both the list price and the net price of both the drugs, and why the company was charging a higher price for the weight loss drug Wegovy than Ozempic, which contains the same compound.
Novo Nordisk stock: The weight-loss drug leader hit a buy point in the recent stock market rebound and is one of the best stocks to watch.